In a significant move to curb malpractice within the pharmaceutical sector, the Supreme Court of India has directed the Central government to constitute a high-level committee. This panel's mandate will be to consider various suggestions and recommend measures to prevent drug manufacturing companies from engaging in unethical marketing practices.
Regulating Pharma Marketing Practices
A bench comprising Justices Vikram Nath and Sandeep Mehta issued the directive on Thursday, emphasizing the need for robust regulation in the industry. The committee is tasked with reviewing representations and proposals before submitting its recommendations to the government. The Centre has also been instructed to present the committee's final report to the Supreme Court for further consideration.
Background of the Directive
The court's order stems from a 2021 petition filed by the Federation of Medical and Sales Representatives Association of India (FMRSAI). This petition sought urgent intervention to regulate what it described as unethical marketing tactics employed by pharmaceutical companies. These alleged practices include offering lavish gifts, travel incentives, and other benefits to doctors to promote specific medicines, potentially influencing prescription patterns.
The FMRSAI's plea specifically requested the Supreme Court to establish guidelines to control and regulate such activities until a comprehensive and effective law could be enacted to address the issue.
Government's Acknowledgment and Interim Measures
During a hearing on September 8, the Central government had informed the court of its intention to form a three-member panel. This panel's purpose was to examine the issue thoroughly and propose a statutory framework to ensure pharmaceutical companies adhere to ethical standards. The government acknowledged the necessity of strengthening existing mechanisms governing pharmaceutical marketing.
Discussions had reportedly taken place to determine whether a statutory framework was indeed required and, if so, its appropriate form. Until the newly directed committee submits its report and a decision is made on the proposed statutory framework, the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024, will continue to govern the sector. The Centre is expected to file a compliance affidavit by January 29, when the matter is next listed for hearing.
"The Supreme Court's proactive stance underscores the critical need for transparency and ethics in the pharmaceutical industry, directly impacting public health and trust," said a legal expert following the ruling.
This judicial intervention highlights growing concerns over the influence of marketing strategies on medical prescriptions and aims to foster a more ethical environment for healthcare professionals and patients alike.